bioAffinity (BIAF) Fundamental Analysis: Revenue, Earnings & Valuation

0.87 / 10

Underperform

Fundamentals rate Underperform with a 0.9/10 quality score. Profit‑MV and cash‑up show modest strength, while cash‑MV, ROE and asset metrics are weak, yielding a guarded outlook.

Analysis Checks(3/10)

ROA (%)

Value-170.65

Score0/3

Weight15.37%

1M Return-6.12%

Annualized return on equity (%)

Value-301.83

Score0/3

Weight14.69%

1M Return-5.73%

Profit-MV

Value0.68

Score2/3

Weight-14.05%

1M Return3.26%

Cash-UP

Value-0.16

Score2/3

Weight12.82%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value-170.65

Score0/3

Weight15.37%

1M Return-6.12%

ROE (diluted) (%)

Value-204.87

Score0/3

Weight15.43%

1M Return-5.82%

Asset-MV

Value-0.55

Score0/3

Weight11.26%

1M Return-3.34%

ROE (%)

Value-301.83

Score0/3

Weight14.69%

1M Return-5.73%

Cash-MV

Value0.03

Score1/3

Weight11.05%

1M Return-3.56%

Net profit / Total profit (%)

Value100.30

Score2/3

Weight3.36%

1M Return-0.89%

Is BIAF fundamentally strong?

BIAF scores 0.87/10 on fundamentals and holds a Premium valuation at present. Backed by its -301.83% ROE, -241.96% net margin, -1.20 P/E ratio, 2.45 P/B ratio, and 61.51% earnings growth, these metrics solidify its Underperform investment rating.